Modern Vaccines Adjuvants Formulation

2-4 May 2018, LUMC – Leiden University Medical Center, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 2nd May 2018

08.30 Onwards
Registration

SESSION 1:
PLENARY SESSION I

Moderator: Tom H.M. Ottenhoff (Leiden University Medical Center, Leiden, The Netherlands)

09.30-10.00
‘Defined adjuvants for cancer vaccines’

Ferry A. Ossendorp (Leiden University Medical Center, Leiden, The Netherlands)

10.00-10.30
‘Translational Vaccinology: A myth?’

Geert Vanden Bossche (COIMEVA LLC, Huldenberg, Belgium)

10.30-11.00
‘Translating adjuvant science to the real world: Not a 100 metre dash’

Raja Rajaram (Seqirus, Maidenhead, Berkshire, UK)

11.00-11.30
Coffee Break

SESSION 2:
PLENARY SESSION II

Moderator: Geert Vanden Bossche (COIMEVA LLC, Huldenberg, Belgium)

11.30-12.00
‘Host directed therapy by immunostimulants and novel compounds’
Tom H.M. Ottenhoff (Leiden University Medical Center, Leiden, The Netherlands)

12.00-12.30
‘Distinct adjuvants requirement for induction of T versus B cell responses’
Martin Bachmann (University of Berne, Berne, Switzerland / University of Oxford, Oxford, UK)

12.30-13.00
‘Vaccine formulation a matter for accomplishment’

Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)

13.00-14.00
Lunch Break

SESSION 3:
PLENARY SESSION III

Moderator: Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)

14.00-14.30
‘Anti-tumour vaccines: An update’

Kees Melief (ISA-Pharmaceuticals BV, Leiden, The Netherlands)

14.30-15.00
‘Immune-engineering antigens for better vaccine design’

Lenny Moise (EpiVax Inc., Providence, Rhode Island, USA)

15.00-15.30
‘Opportunities and challenges in characterizing the safety of new adjuvants’

Thomas Verstraeten, Marc Baay and Kaatje Bollaerts (P95 Epidemiology and Pharmacovigilance Services, Leuven, Belgium)

15.30-16.00
Tea Break

SESSION 4:
VIRUS TOPICS

Moderator: Martin Bachmann (University of Berne, Berne, Switzerland / University of Oxford, Oxford, UK)

16.00-16.30
‘A virosomal RSV vaccine containing the 3D-PHAD® adjuvant based on thermostable virus’

Toon Stegmann (Mymetics BV, Leiden, The Netherlands)

16.30-17.00
‘Mucosal immunity may be the missing link to improve the poor and variable efficacy of flu vaccines: Protection by intranasal vaccination with Nanostat®-Pandemic flu (rH5) in ferrets’

Ali Fattom, Doug Smith and Vira Bitko (NanoBio Corp., Ann Arbor, Michigan, USA)

17.00-17.30
‘VLPs for veterinary medicine: Transforming the success of human monoclonal antibodies into effective and affordable medicines for companion animals’
Martin Bachmann (Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

 

MVAF 2018 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2018 Sponsors

  • Bioaster
  • hVIVO
  • CureVac
  • Aldevron
  • Inovio Pharmaceuticals
  • Seppic
  • NatureGeneTherapy.com
  • VaxArt
  • IDRI
  • Brenntag
  • Intravacc
  • EVI
  • DNAvaccine.com
  • Sanofi Pasteur

MVAF 2018 Downloads

MVAF 2018 Leaflet

MVAF 2018 Mailing List

Name
E-mail Address
What is 3+2-1?